Dashboard
Manage Tickers

JAZZ Jazz Pharmaceuticals plc

Nasdaq jazzpharma.com


$ 136.67 $ -0.63 (-0.46 %)    

Wednesday, 12-Nov-2025 15:10:46 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 619.43 $ -5.38 (-0.86 %)
DIA $ 482.88 $ 2.32 (0.48 %)
SPY $ 682.46 $ -2.33 (-0.34 %)
TLT $ 90.08 $ 0.14 (0.15 %)
GLD $ 386.03 $ 5.88 (1.55 %)
$ 137.11
$ 139.12
$ 136.63 x 2
$ 136.77 x 100
$ 136.44 - $ 140.43
$ 95.49 - $ 148.06
1,011,414
na
8.33B
$ 0.62
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 02-26-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 03-01-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-03-2022 06-30-2022 10-Q
15 05-04-2022 03-31-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-03-2021 06-30-2021 10-Q
19 05-04-2021 03-31-2021 10-Q
20 02-23-2021 12-31-2020 10-K
21 11-02-2020 09-30-2020 10-Q
22 08-04-2020 06-30-2020 10-Q
23 05-05-2020 03-31-2020 10-Q
24 02-25-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 02-26-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-08-2018 03-31-2018 10-Q
32 02-27-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-08-2017 06-30-2017 10-Q
35 05-09-2017 03-31-2017 10-Q
36 02-28-2017 12-31-2016 10-K
37 11-08-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-10-2016 03-31-2016 10-Q
40 02-23-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jazz-pharma-to-highlight-both-clinical-and-preclinical-research-evaluating-modeyso-and-new-preclinical-data-featuring-jzp3507-in-cns-tumors-at-2025-sno-annual-meeting
Jazz Pharma To Highlight Both Clinical And...
11/11/2025 12:48:19

Data highlight continued progress in Jazz's brain tumor research and demonstrate the company's commitment to advancing ...

rbc-capital-maintains-outperform-on-jazz-pharmaceuticals-raises-price-target-to-155
RBC Capital Maintains Outperform on Jazz P...
11/06/2025 16:15:44

RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price targ...

jazz-pharmaceuticals-raises-fy2025-gaap-eps-guidance-from-925-750-to-710-520-vs-776-est
Jazz Pharmaceuticals Raises FY2025 GAAP EP...
11/05/2025 21:18:15

Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2025 GAAP EPS guidance from $(9.25)-$(7.50) to $(7.10)-$(5.20) vs $(7.76) analyst e...

jazz-pharmaceuticals-raises-fy2025-adj-eps-guidance-from-480-560-to-765-845-vs-533-est-narrows-fy2025-sales-guidance-from-4150b-4300b-to-4175b-4275b-vs-4221b-est
Jazz Pharmaceuticals Raises FY2025 Adj EPS...
11/05/2025 21:18:04

Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2025 Adj EPS guidance from $4.80-$5.60 to $7.65-$8.45 vs $5.33 analyst estimate. Na...

jazz-pharmaceuticals-q3-adj-eps-813-beats-592-estimate-sales-1126b-beat-1109b-estimate
Jazz Pharmaceuticals Q3 Adj. EPS $8.13 Bea...
11/05/2025 21:15:16

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $8.13 per share which beat the analyst consensus estimate of ...

earnings-scheduled-for-november-5-2025
Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

insights-into-jazz-pharmaceuticalss-upcoming-earnings
Insights into Jazz Pharmaceuticals's Upcom...
11/04/2025 17:01:12

jp-morgan-maintains-overweight-on-jazz-pharmaceuticals-lowers-price-target-to-199
JP Morgan Maintains Overweight on Jazz Pha...
10/27/2025 14:32:55

JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and lowers the price target fro...

alkermes-strikes-21-billion-avadel-deal-gains-access-to-narcolepsy-drug-lumryz
Alkermes Strikes $2.1 Billion Avadel Deal,...
10/22/2025 19:18:55

Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicin...

Core News & Articles
Avadel Pharma Announces Global Settlement ...
10/22/2025 10:34:33

Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, tod...

deep-dive-into-jazz-pharmaceuticals-stock-analyst-perspectives-9-ratings
Deep Dive Into Jazz Pharmaceuticals Stock:...
10/20/2025 18:35:16

morgan-stanley-maintains-overweight-on-jazz-pharmaceuticals-raises-price-target-to-180
Morgan Stanley Maintains Overweight on Jaz...
10/20/2025 15:36:45

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price targ...

3-small-cap-stocks-to-play-as-the-bantamweights-break-out-on-wall-street
3 Small Cap Stocks To Play As The Bantamwe...
10/17/2025 17:47:30

scisparc-expands-biotech-ambitions-buys-stake-in-miza-iii-ventures
SciSparc Expands Biotech Ambitions, Buys S...
10/15/2025 13:34:30

SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza ...

scisparc-and-automax-call-off-merger
SciSparc And AutoMax Call Off Merger
10/06/2025 12:55:03

SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation.

fda-approves-lurbinectedin-in-combination-with-atezolizumab-or-atezolizumab-and-hyaluronidase-tqjs-for-extensive-stage-small-cell-lung-cancer
FDA Approves Lurbinectedin In Combination ...
10/02/2025 19:35:24

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lurbinectedin-combination-atezolizumab-or-atezolizu...

deep-dive-into-jazz-pharmaceuticals-stock-analyst-perspectives-9-ratings
Deep Dive Into Jazz Pharmaceuticals Stock:...
09/24/2025 14:01:57

morgan-stanley-maintains-overweight-on-jazz-pharmaceuticals-raises-price-target-to-167
Morgan Stanley Maintains Overweight on Jaz...
09/24/2025 13:25:43

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price targ...

jazz-pharmas-xywav-shows-phase-4-results-improving-sleep-and-daytime-alertness-in-narcolepsy-hypersomnia-patients
Jazz Pharma's Xywav Shows Phase 4 Results ...
09/22/2025 11:46:31

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new real-world evidence and Phase 4 data reinforcing the value of Xywav...

Core News & Articles
Court Orders Avadel CNS To Pay 3.85% Ongoi...
09/17/2025 15:57:16

As previously disclosed, on May 12, 2021, Jazz Pharmaceuticals, Inc. ("Jazz") filed a formal complaint initiating a law...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION